NaNots are a new nano-medical platform consisting of in vivo “scavengers” that remove specific circulating molecular signals or signal inhibitors that drive or enable disease progression. NaNots can potentially treat a broad range of diseases. Our first NaNot – currently undergoing animal trials – is a scavenger of one class of tumor-generated immune inhibitors, as a treatment for solid tumor cancers.
NaNots are based on several interrelated disciplines, including cell signaling, oncology, immunology, biochemistry and nano engineering, among others. Our team is interdisciplinary and is guided by world-class advisors. We build on thousands of published studies – some of which will soon be posted here – and are also running our own target analyses and clinical studies in addition to our core engineering efforts.
In this section, you can learn more about NaNots, including how they compare with antibody (Ab) drugs. If you have access to the confidential sections of our site, you can also learn more about the targets that NaNots can capture and which diseases they can potentially treat.
What’s a NaNot?
NaNots are injectable nanoparticles that “scavenge” aberrant cell signals and/or signal inhibitors circulating in blood, which drive virtually all major diseases, including all solid tumor cancers and autoimmune diseases.
NaNots can be “programmed” to treat different diseases by changing the signals/inhibitors they capture.
NaNots do not target cells of any type and in fact are shielded against ALL cell membrane interactions – greatly reducing or eliminating unintended effects
NaNots are fully biocompatible; they are injected like a drug and cleared by macrophages after they capture their targets.
NaNots were invented by founders of NaNotics, LLC, based in Marin and London. The company closed Series A funding in July, 2016 and received 2 broad patents in 2017, with 7 more patent families pending. The company closed an A2 round in May, 2018
Advantages of NaNots vs Ab Drugs
- Any disease driven by intercellular signals or inhibitors can potentially be treated by NaNots more effectively than drugs
- More than half of the $1 trillion global pharmaceutical market is based on drugs that could be replaced by NaNots
- NaNotics, LLC is planning a factory for designing, testing & fabricating new NaNots every few months
- The NaNot platform goes beyond disease to include aging itself. Many pathogenic molecules driving age-related decline have been identified.
- Rapid action – 3-10 minutes – bioactivity then terminates
- No tissue targeting required – targets find NaNots in blood via diffusion (avoids prime reason prior nanomedicines have failed)
- No loss of efficacy with repeated use – NaNots do not expose capture agent to B cell recognition so no build-up of anti-drug antibodies – a common problem with Ab drugs
- Detailed efficacy data available under NDA
- Targets only soluble forms of signal / inhibitor molecules – avoiding all cell membrane interactions, the cause of many drug side effects
- No stimulation of immune function required – immune efficacy can be enhanced just by scavenging inhibitors
- NaNots have much better safety profiles than drugs (5-10% of hospital deaths are due to overdoses)
- NaNots do not cross-react – multiple NaNots can be administered in same patient at same time
- Our first NaNot has passed both in vitro & in vivo (mouse & rat) safety studies
- Targets can be quantified in each patient in advance of treatment, enabling precise dosing of correct NaNot types
- Target quantification enables personalized medicine without costly personalized therapeutics (unlike cell therapies)
- Temporal precision of nanoscavenging allows previously
unfeasible sequential therapeutics
– e.g. sepsis, which has multiple phases that each require distinct therapeutic intervention
Development Time & Cost (Pre-Clinical)
The NaNot development process is significantly faster and cheaper than the process of developing antibody drugs. The problem with most drugs is that their targets have both pathogenic and homeostatic forms; drug designers must iterate repeatedly between drug design and animal trials, before arriving at a favorable balance of efficacy and safety. NaNot engineers, by comparison, can focus on efficacy during development because NaNot capture agents are sequestered behind shields that block cellular interactions and associated side effects. We project a per-NaNot development time through mouse efficacy trials of 8 months – dropping to 3 months within 3 years – versus 48+ months for drug design.